Alloplex Biotherapeutics is a company that has developed a highly-differentiated, non-engineered, tumor-agnostic cellular therapy platform with broad anti-tumor activity. They have created SUPLEXA therapeutic cells which are individualized, non-engineered cells that can be used to treat cancer.
However, they are dedicated to exploring the higher order combinatorial space of immunomodulators to develop an effective anti-tumor vaccine.
However, they are dedicated to exploring the higher order combinatorial space of immunomodulators to develop an effective anti-tumor vaccine.
Location: United States, Massachusetts, Boston
Employees: 1-10
Founded date: 2016
Mentions in press and media 6
| Date | Title | Description |
| 01.11.2024 | Revolutionizing Cancer Treatment: The Promise of SUPLEXA | In the battle against cancer, a new weapon has emerged from the laboratories of Australia. SUPLEXA, a groundbreaking treatment, is turning the tide by harnessing the power of the patient’s own immune cells. This innovative approach is not j... |
| 31.10.2024 | Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough | BOSTON, Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the patient's own immune cells to fight cancer. &qu... |
| 31.10.2024 | Breakthrough Australian Cancer trial: retraining immune cells offers new hope for patients | ADELAIDE, Australia and BOSTON, Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, Australian patients with advanced-stage cancer have benefited from SUPLEXA, a personalised treatment that trains the patient's ow... |
| 19.08.2021 | Daewoong Pharmaceutical and Hanall Biopharma Invest $1M USD in Alloplex Biotherapeutics | SEOUL, South Korea, Aug. 19, 2021 /PRNewswire/ -- Daewoong Pharmaceutical and Hanall Biopharma of South Korea are expanding their global open collaboration initiative by investing in Alloplex Biotherapeutics, an emerging Boston-based biotec... |
| 25.06.2021 | Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021 | NEWPORT BEACH, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Roth Capital Partners (“Roth”), www.roth.com, is set to virtually present the Roth Virtual Healthcare Private Company Forum on June 28th, 2021. This event will con... |
| - | Alloplex Biotherapeutics | “Alloplex has developed a highly-differentiated, non-engineered, tumor-agnostic cellular therapy platform with broad anti-tumor activity.” |